Recital 19, Regulation (EU) 2017/1001

In forcecited 1×

Appropriate measures should be taken with a view to ensuring the smooth transit of generic medicines. With respect to international non-proprietary names (INN) as globally recognised generic names for active substances in pharmaceutical preparations, it is vital to take due account of the existing limitations on the effect of EU trade mark rights. Consequently, the proprietor of an EU trade mark should not have the right to prevent a third party from bringing goods into the Union without being released for free circulation there, based upon similarities between the INN for the active ingredient in the medicines and the trade mark.

  • Judgment of the General Court (Fifth Chamber, Extended Composition) of 20 September 2019. BASF Grenzach GmbH v European Chemicals Agency.Decision

    Finally, it should be noted that the nature of the tasks of the EUIPO and of the decisions of that office is not comparable to that of the tasks and decisions of the ECHA. As is apparent from recital 27 of Regulation 2017/1001, it is for …

    20 Sep 2019 · 62017TJ0125